Houlihan Lokey Advises Data Horizon

Houlihan Lokey is pleased to announce that Data Horizon has agreed to sell its shares to DeNA through tender offer and third-party allotment and has agreed to acquire DeSC Healthcare DeNA’s subsidiary engaged in data health, data utilization, and healthcare DX from DeNA.The transaction closed on October 3, 2022.

Headquartered in Hiroshima, Japan, Data Horizon (TYO:3628) was founded on 25 March 1982 with a mission to contribute to the cost optimization of medical expenditures and the improvement of QOL for all patients. Driven by its goal of creating a healthier future through the use of medical big data, Data Horizon provides clients with high-quality healthcare-related services, including receipt data analysis and data health PDCA planning, insurance claims visualization, and data health services focused on QOL improvement. Data Horizon also owns proprietary-licensed technology for grouping medical expenses and managing each stage of the disease.

DeNA Co., Ltd. (TYO:2432) engages in the development and operations of a wide range of mobile and online applications and services, including games, e-commerce, and entertainment content distribution. Its healthcare segment has launched various successful digital healthcare services such as DeNA Healthcare, which supports a variety of online healthcare services and R&D projects, genetic-testing service MYCODE, health insurance support app kencom, and walking app Aruite Otoku, among others. The company was founded on 4 March 1999 and is headquartered in Tokyo, Japan.

DeSC Healthcare, Inc. (DeSC), which was established as a joint venture between DeNA and Sumitomo Corp. (TYO:8053), focuses on data healthcare, data utilization, and healthcare DX. In April 2020, DeSC entered into a business alliance agreement with Data Horizon in the area of data health and has since developed close ties.

DeNA believes that strengthening the relationship with Data Horizon and building a seamless cooperative platform will accelerate both companies' aim to increase healthy life expectancy and realize a primary balance of medical expenditures in Japan. This deal will also allow the two companies to further fortify the partnership and promote business opportunities for Data Horizon as part of the DeNA Group, resulting in improved corporate value for both companies.

Data Horizon also believes that acquiring DeSC and integrating its database is an effective way to expand market share and profitability and improve other financial fundamentals.

This transaction marks another deal in the Japanese data health space and the second deal between Data Horizon and DNA advised by Houlihan Lokey in the past two years, reinforcing the firm's sector knowledge and strong client relationships.

Houlihan Lokey acted as sole leading financial advisor to Data Horizon.

RELATED: Healthcare